Both Acasti Pharma Inc. (NASDAQ:ACST) and Therapix Biosciences Ltd. (NASDAQ:TRPX) are each other’s competitor in the Biotechnology industry. Thus the compare of their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acasti Pharma Inc. | N/A | 0.00 | N/A | -1.22 | 0.00 |
| Therapix Biosciences Ltd. | N/A | 0.00 | 7.71M | -1.56 | 0.00 |
Demonstrates Acasti Pharma Inc. and Therapix Biosciences Ltd. earnings per share (EPS), top-line revenue and valuation.
Profitability
Table 2 represents Acasti Pharma Inc. (NASDAQ:ACST) and Therapix Biosciences Ltd. (NASDAQ:TRPX)’s return on equity, net margins and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Acasti Pharma Inc. | 0.00% | 0% | 0% |
| Therapix Biosciences Ltd. | 0.00% | 0% | 0% |
Institutional and Insider Ownership
The shares of both Acasti Pharma Inc. and Therapix Biosciences Ltd. are owned by institutional investors at 0.64% and 0% respectively. About 8.49% of Acasti Pharma Inc.’s share are owned by insiders. On the other hand, insiders owned about 2.08% of Therapix Biosciences Ltd.’s shares.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Acasti Pharma Inc. | -11.36% | -35.29% | 14.73% | -3.43% | -57.56% | -31.36% |
| Therapix Biosciences Ltd. | -5.19% | -36.14% | 31.19% | 20.18% | 2.08% | -0.75% |
For the past year Acasti Pharma Inc.’s stock price has bigger decline than Therapix Biosciences Ltd.
Summary
Acasti Pharma Inc. beats on 2 of the 3 factors Therapix Biosciences Ltd.
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome (TS); and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Tel Aviv, Israel.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
